WallStreetZenWallStreetZen

NASDAQ: HRMY
Harmony Biosciences Holdings Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for HRMY

Based on 7 analysts offering 12 month price targets for Harmony Biosciences Holdings Inc

Min Forecast
$28.00+1.41%
Avg Forecast
$42.86+55.22%
Max Forecast
$55.00+99.2%

Should I buy or sell HRMY stock?

Based on 7 analysts offering ratings for Harmony Biosciences Holdings Inc.

Buy
Strong Buy
2 analysts 28.57%
Buy
3 analysts 42.86%
Hold
1 analysts 14.29%
Sell
1 analysts 14.29%
Strong Sell
0 analysts 0%
Although HRMY's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates HRMY as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their HRMY stock forecasts and price targets.

HRMY stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-02-25
lockedlocked$00.00+00.00%2026-02-25
lockedlocked$00.00+00.00%2026-02-25
lockedlocked$00.00+00.00%2026-02-25
lockedlocked$00.00+00.00%2026-02-11
Truist Securities
Top 13%
88
Strong BuyMaintains$45.00+62.98%2026-01-08
Mizuho
Top 6%
95
BuyMaintains$46.00+66.61%2025-12-01
Deutsche Bank
Top 9%
92
Strong BuyMaintains$36.00+30.39%2025-09-25

1 of 1

Forecast return on equity

Is HRMY forecast to generate an efficient return?

Company
21.79%
Industry
66.72%
Market
181.06%
HRMY's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is HRMY forecast to generate an efficient return on assets?

Company
14.91%
Industry
32.08%
HRMY is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

HRMY earnings per share forecast

What is HRMY's earnings per share in the next 3 years based on estimates from 13 analysts?

Avg 1 year Forecast
$3.62+31.26%
Avg 2 year Forecast
$4.31+56.1%
Avg 3 year Forecast
$5.06+83.45%
HRMY's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

HRMY revenue forecast

What is HRMY's revenue in the next 3 years based on estimates from 13 analysts?

Avg 1 year Forecast
$1.0B+19.87%
Avg 2 year Forecast
$1.2B+34.84%
Avg 3 year Forecast
$1.3B+51.65%
HRMY's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

HRMY earnings growth forecast

How is HRMY forecast to perform vs Biotechnology companies and vs the US market?

Company
22.3%
Industry
12%
Market
36.33%
HRMY's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
HRMY's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
HRMY's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

HRMY revenue growth forecast

How is HRMY forecast to perform vs Biotechnology companies and vs the US market?

Company
14.79%
Industry
37.55%
Market
13.46%
HRMY's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
HRMY's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

HRMY vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
HRMY$27.61$42.86+55.22%Buy
NBTX$33.07$26.00-21.38%Strong Buy
IMCR$30.86$65.20+111.28%Buy
IOVA$3.96$9.20+132.32%Buy
AGIO$27.85$37.63+35.10%Buy
View Top Biotech Stocks

Harmony Biosciences Holdings Stock Forecast FAQ

Is Harmony Biosciences Holdings Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 7 Wall Street analysts covering (NASDAQ: HRMY) stock is to Buy HRMY stock.

Out of 7 analysts, 2 (28.57%) are recommending HRMY as a Strong Buy, 3 (42.86%) are recommending HRMY as a Buy, 1 (14.29%) are recommending HRMY as a Hold, 1 (14.29%) are recommending HRMY as a Sell, and 0 (0%) are recommending HRMY as a Strong Sell.

If you're new to stock investing, here's how to buy Harmony Biosciences Holdings stock.

What is HRMY's earnings growth forecast for 2026-2028?

(NASDAQ: HRMY) Harmony Biosciences Holdings's forecast annual earnings growth rate of 22.3% is forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.33%.

Harmony Biosciences Holdings's earnings in 2026 is $158,687,000.On average, 13 Wall Street analysts forecast HRMY's earnings for 2026 to be $209,544,976, with the lowest HRMY earnings forecast at $142,785,340, and the highest HRMY earnings forecast at $267,223,637. On average, 13 Wall Street analysts forecast HRMY's earnings for 2027 to be $249,200,501, with the lowest HRMY earnings forecast at $175,719,785, and the highest HRMY earnings forecast at $385,044,967.

In 2028, HRMY is forecast to generate $292,864,381 in earnings, with the lowest earnings forecast at $82,191,512 and the highest earnings forecast at $393,547,538.

What is HRMY's revenue growth forecast for 2026-2028?

(NASDAQ: HRMY) Harmony Biosciences Holdings's forecast annual revenue growth rate of 14.79% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.55%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.46%.

Harmony Biosciences Holdings's revenue in 2026 is $868,453,000.On average, 13 Wall Street analysts forecast HRMY's revenue for 2026 to be $60,212,079,174, with the lowest HRMY revenue forecast at $55,760,087,114, and the highest HRMY revenue forecast at $63,740,356,628. On average, 13 Wall Street analysts forecast HRMY's revenue for 2027 to be $67,731,358,994, with the lowest HRMY revenue forecast at $53,129,495,990, and the highest HRMY revenue forecast at $76,928,016,620.

In 2028, HRMY is forecast to generate $76,176,088,638 in revenue, with the lowest revenue forecast at $65,186,371,978 and the highest revenue forecast at $89,479,429,858.

What is HRMY's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: HRMY) forecast ROA is 14.91%, which is lower than the forecast US Biotechnology industry average of 32.08%.

What is HRMY's Price Target?

According to 7 Wall Street analysts that have issued a 1 year HRMY price target, the average HRMY price target is $42.86, with the highest HRMY stock price forecast at $55.00 and the lowest HRMY stock price forecast at $28.00.

On average, Wall Street analysts predict that Harmony Biosciences Holdings's share price could reach $42.86 by Feb 25, 2027. The average Harmony Biosciences Holdings stock price prediction forecasts a potential upside of 55.22% from the current HRMY share price of $27.61.

What is HRMY's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: HRMY) Harmony Biosciences Holdings's current Earnings Per Share (EPS) is $2.76. On average, analysts forecast that HRMY's EPS will be $3.62 for 2026, with the lowest EPS forecast at $2.47, and the highest EPS forecast at $4.62. On average, analysts forecast that HRMY's EPS will be $4.31 for 2027, with the lowest EPS forecast at $3.04, and the highest EPS forecast at $6.66. In 2028, HRMY's EPS is forecast to hit $5.06 (min: $1.42, max: $6.80).

What is HRMY's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: HRMY) forecast ROE is 21.79%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.